EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan

Kensuke Yoshida, Ibuki Kubo, Anna Kiyomi, Yujiro Homma, Qiliang Zhou, Shinobu Imai, Munetoshi Sugiura

Anticancer Research · 2026

DOI: 10.21873/anticanres.18402 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Anticancer Research, 2026. Verfasst von Kensuke Yoshida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; yoshida@toyaku.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleJapanRetrospective StudiesAgedMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

Hepatocellular carcinomaSTRIDE regimenimmune checkpoint inhibitorsreal-world datatreatment selection

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Laboratory of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; yoshida@toyaku.ac.jp.
  • Laboratory of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Department of Medical Oncology, Niigata City General Hospital, Niigata, Japan.
  • Department of Pharmacoepidemiology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.

Zitieren

APA

Yoshida, K., Kubo, I., Kiyomi, A., Homma, Y., Zhou, Q., Imai, S., & Sugiura, M. (2026). Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan. Anticancer Research. https://doi.org/10.21873/anticanres.18402

Vancouver

Yoshida K, Kubo I, Kiyomi A, Homma Y, Zhou Q, Imai S, et al. Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan. Anticancer Research. 2026. doi:10.21873/anticanres.18402

BibTeX
@article{Yoshida2026,
  author = {Yoshida, Kensuke and Kubo, Ibuki and Kiyomi, Anna and Homma, Yujiro and Zhou, Qiliang and Imai, Shinobu and Sugiura, Munetoshi},
  title = {Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18402}
}
Kostenlos starten →